The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Addition of darolutamide to first line treatment of metastatic castration-resistant prostate cancer (mCRPC): A randomized open label phase II trial (SAKK 08/23).
 
Ursula Vogl
Honoraria - Astellas Oncology (Inst); Bayer (Inst); BMS GmbH & Co. KG (Inst); Grasso Consulting (Inst); Healthbook; Ipsen (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis Institutes for BioMedical Research (Inst); Pfizer (Inst)
Consulting or Advisory Role - Astellas Oncology (Inst); Bayer HealthCare Pharmacuticals (Inst); BMS GmbH & Co. KG (Inst); Ipsen (Inst); Janssen (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Research Funding - Fond Action (Inst)
Expert Testimony - Astellas Oncology (Inst); Merck KGaA (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen-Cilag
 
Katrin Eckhardt
No Relationships to Disclose
 
Katrin Gobat
No Relationships to Disclose
 
Silke Gillessen
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); InnoMedica (Inst); Ipsen (Inst); Macrogenics (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); PeerVoice (Inst); Pfizer (Inst)
Speakers' Bureau - AdMeTech Foundation (Inst); ASCO GU (Inst); Avalere Health (Inst); EPG Health (Inst); ESMO; German-speaking European School of Oncology (DESO); Intellisphere (Inst); Meister ConCept GmbH (Inst); Schweizerische Gesellschaft für Medizinische Onkologie; Silvia Grasso Consulting (Inst); Swiss Group for Clinical Cancer Research (SAKK); Swiss Group for Clinical Cancer Research (SAKK) (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Gilead Sciences; Intellisphere
 
Richard Cathomas
Honoraria - Astellas Pharma (Inst); Janssen-Cilag; Merck KGaA (Inst); Sandoz (Inst)
Consulting or Advisory Role - Accord Healthcare (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Ipsen (Inst)